Cancer Causes & Control

, Volume 22, Issue 2, pp 291–299 | Cite as

Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study

  • Wegene Borena
  • Tanja Stocks
  • Håkan Jonsson
  • Susanne Strohmaier
  • Gabriele Nagel
  • Tone Bjørge
  • Jonas Manjer
  • Göran Hallmans
  • Randi Selmer
  • Martin Almquist
  • Christel Häggström
  • Anders Engeland
  • Steinar Tretli
  • Hans Concin
  • Alexander Strasak
  • Pär Stattin
  • Hanno Ulmer
Original paper

Abstract

Objective

To assess the association between serum triglyceride levels and cancer risk.

Methods

The metabolic syndrome and cancer project (Me-Can) includes cohorts from Norway, Austria, and Sweden; the current study included data on 257,585 men and 256,512 women. The mean age at study entry was 43.8 years for men and 44.2 years for women. The mean follow-up time was 13.4 years (SD = 8.5) for men and 11.9 years (SD = 7.2) for women. Excluding the first year of follow-up, 23,060 men and 15,686 women were diagnosed with cancer. Cox regression models were used to calculate relative risk (RR) of cancer for triglyceride levels in quintiles and as a continuous variable. RRs were corrected for random error by use of regression dilution ratio.

Results

Relative risk for top quintile versus bottom quintile of triglycerides of overall cancer was 1.16 (95% confidence interval 1.06–1.26) in men and 1.15 (1.05–1.27) in women. For specific cancers, significant increases for top quintile versus bottom quintile of triglycerides among men were found for cancers of the colon, respiratory tract, the kidney, melanoma and thyroid and among women, for respiratory, cervical, and non-melanoma skin cancers.

Conclusion

Data from our study provided evidence for a possible role of serum triglycerides in cancer development.

Keywords

Lipids Prospective study Cancer incidence 

Supplementary material

10552_2010_9697_MOESM1_ESM.docx (23 kb)
Supplementary material 1 (DOCX 22 kb)
10552_2010_9697_MOESM2_ESM.docx (15 kb)
Supplementary material 2 (DOCX 14 kb)

References

  1. 1.
    Sarwar N, Danesh J, Eiriksdottir G et al (2007) Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation 115(4):450–458CrossRefPubMedGoogle Scholar
  2. 2.
    Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298(3):309–316CrossRefPubMedGoogle Scholar
  3. 3.
    Ridker PM (2008) Fasting versus non-fasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test? Clin Chem 54(1):11–13CrossRefPubMedGoogle Scholar
  4. 4.
    Iso H, Naito Y, Sato S et al (2001) Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 153(5):490–499CrossRefPubMedGoogle Scholar
  5. 5.
    Cambien F, Jacqueson A, Richard JL, Warnet JM, Ducimetiere P, Claude JR (1986) Is the level of serum triglyceride a significant predictor of coronary death in “normocholesterolemic” subjects? The Paris Prospective Study. Am J Epidemiol 124(4):624–632PubMedGoogle Scholar
  6. 6.
    Fontbonne A, Eschwège E, Cambien F et al (1989) Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 32(5):300–304CrossRefPubMedGoogle Scholar
  7. 7.
    Giovannucci E (2007) Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 86(3):836–842Google Scholar
  8. 8.
    Giovannucci E (2001) Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131:3109–3120Google Scholar
  9. 9.
    Cowey S, Hardy RW (2006) The metabolic syndrome: a high-risk state for cancer? Am J Pathol 169:1505–1522CrossRefPubMedGoogle Scholar
  10. 10.
    Tulinius H, Sigfússon N, Sigvaldason H, Bjarnadóttir K, Tryggvadóttir L (1997) Risk factors for malignant diseases: a cohort study on a population of 22, 946 Icelanders. Cancer Epidemiol Biomarkers Prev 6(11):863–873PubMedGoogle Scholar
  11. 11.
    Ulmer H, Borena W, Rapp K et al (2009) Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer 101(7):120–126CrossRefGoogle Scholar
  12. 12.
    McKeown-Eyssen G (1994) Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 3(8):687–695PubMedGoogle Scholar
  13. 13.
    Tsushima M, Nomura AM, Lee J, Stemmermann GN (2005) Prospective study of the association of serum triglyceride and glucose with colorectal cancer. Dig Dis Sci 50(3):499–505CrossRefPubMedGoogle Scholar
  14. 14.
    Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L (2001) Breast cancer risk in ex-smokers in relation to body mass index, weight gain and blood lipid levels. Eur J Cancer Prev 10(3):281–287CrossRefPubMedGoogle Scholar
  15. 15.
    Gaard M, Tretli S, Urdal P (1994) Risk of breast cancer in relation to blood lipids: a prospective study of 31, 209 Norwegian women. Cancer Causes Control 5(6):501–509CrossRefPubMedGoogle Scholar
  16. 16.
    Lund HL, Wisloff TF, Holme I, Nafstad P (2006) Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 164:769–774CrossRefGoogle Scholar
  17. 17.
    Tande AJ, Platz EA, Folsom AR (2006) The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 164:1094–1102CrossRefPubMedGoogle Scholar
  18. 18.
    Emberson JR, Whincup PH, Morris RW, Walker M, Lowe GD, Rumley A (2004) Extent of regression dilution for established and novel coronary risk factors: results from the British Regional Heart Study. Eur J Cardiovasc Prev Rehabil 11(2):125–134CrossRefPubMedGoogle Scholar
  19. 19.
    Stocks T, Borena W, Strohmaier S et al (2009) Cohort profile: the metabolic syndrome and cancer project (Me-Can). Int J Epidemiol 39(3):660–667CrossRefPubMedGoogle Scholar
  20. 20.
    Borena W, Stocks T, Strohmaier S et al (2009) Long-term temporal trends in cardiovascular and metabolic risk factors. Wien Klin Wochenschr 121(19–20):623–630CrossRefPubMedGoogle Scholar
  21. 21.
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106(25):3143–3421Google Scholar
  22. 22.
    Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R (1999) Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 150:341–353PubMedGoogle Scholar
  23. 23.
    Wood AM, White I, Thompson SG, Lewington S, Danesh J (2006) Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27, 247 adults in 15 prospective studies. Int J Epidemiol 35:1570–1578CrossRefPubMedGoogle Scholar
  24. 24.
    Inoue M, Noda M, Kurahashi N et al (2009) Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 18(3):240–247CrossRefPubMedGoogle Scholar
  25. 25.
    Al-Azzawi F, Wahib M (2002) Estrogen and colon cancer: current issues. Climacteric 5(1):3–14PubMedGoogle Scholar
  26. 26.
    Crandall CJ (1999) Estrogen replacement therapy and colon cancer: a clinical review. J Womens Health Gend Based Med 9:1155–1166Google Scholar
  27. 27.
    Brunzell JD (2007) Clinical practice. Hypertriglyceridemia. N Engl J Med 357(10):1009–1017CrossRefPubMedGoogle Scholar
  28. 28.
    Szatrowski TP, Nathan CF (1991) Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51(3):794–798PubMedGoogle Scholar
  29. 29.
    Kamata H, Hirata H (1999) Redox regulation of cellular signalling. Cell Signal 11(1):1–14CrossRefPubMedGoogle Scholar
  30. 30.
    Warnick GR, Nakajima K (2008) Fasting versus nonfasting triglycerides: implications for laboratory measurements. Clin Chem 54(1):14–16CrossRefPubMedGoogle Scholar
  31. 31.
    Yuan G, Al-Shali KZ, Hegele RA (2007) Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 176(8):1113–1120PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Wegene Borena
    • 1
  • Tanja Stocks
    • 2
  • Håkan Jonsson
    • 3
  • Susanne Strohmaier
    • 1
  • Gabriele Nagel
    • 4
  • Tone Bjørge
    • 5
    • 6
  • Jonas Manjer
    • 7
  • Göran Hallmans
    • 8
  • Randi Selmer
    • 6
  • Martin Almquist
    • 9
  • Christel Häggström
    • 2
  • Anders Engeland
    • 6
    • 5
  • Steinar Tretli
    • 10
  • Hans Concin
    • 11
  • Alexander Strasak
    • 1
  • Pär Stattin
    • 2
  • Hanno Ulmer
    • 1
  1. 1.Department of Medical Statistics, Informatics and Health EconomicsInnsbruck Medical UniversityInnsbruckAustria
  2. 2.Department of Surgical and Perioperative Sciences, Urology and AndrologyUmeå UniversityUmeåSweden
  3. 3.Department of Radiation Sciences, OncologyUmeå UniversityUmeåSweden
  4. 4.Institute of EpidemiologyUlm UniversityUlmGermany
  5. 5.Department of Public Health and Primary Health CareUniversity of BergenBergenNorway
  6. 6.Norwegian Institute of Public HealthOslo/BergenNorway
  7. 7.Department of SurgeryMalmö University Hospital, Lund UniversityMalmöSweden
  8. 8.Department of Public Health and Clinical Medicine, Nutritional ResearchUmeå UniversityUmeåSweden
  9. 9.Department of SurgeryLund University Hospital, Lund UniversityMalmöSweden
  10. 10.Cancer Registry of Norway, Institute of Population-Based Cancer ResearchOsloNorway
  11. 11.Agency for Preventive and Social MedicineBregenzAustria

Personalised recommendations